SE2210947T5 - - Google Patents

Info

Publication number
SE2210947T5
SE2210947T5 SE10157183T SE10157183T SE2210947T5 SE 2210947 T5 SE2210947 T5 SE 2210947T5 SE 10157183 T SE10157183 T SE 10157183T SE 10157183 T SE10157183 T SE 10157183T SE 2210947 T5 SE2210947 T5 SE 2210947T5
Authority
SE
Sweden
Prior art keywords
galactosidase
mammalian cell
acid residues
biologically active
sialic acid
Prior art date
Application number
SE10157183T
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25529958&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE2210947(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of SE2210947T5 publication Critical patent/SE2210947T5/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01049—Alpha-N-acetylgalactosaminidase (3.2.1.49)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE10157183T 1992-11-30 1993-11-30 SE2210947T5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/983,451 US5401650A (en) 1990-10-24 1992-11-30 Cloning and expression of biologically active α-galactosidase A

Publications (1)

Publication Number Publication Date
SE2210947T5 true SE2210947T5 (de) 2015-02-03

Family

ID=25529958

Family Applications (1)

Application Number Title Priority Date Filing Date
SE10157183T SE2210947T5 (de) 1992-11-30 1993-11-30

Country Status (14)

Country Link
US (2) US5401650A (de)
EP (4) EP0670896B2 (de)
JP (2) JP4005629B2 (de)
AT (2) ATE464386T1 (de)
AU (1) AU691795B2 (de)
CA (1) CA2150555C (de)
DE (3) DE69334327D1 (de)
DK (3) DK1942189T3 (de)
ES (3) ES2168101T5 (de)
IL (4) IL107814A (de)
LU (2) LU91703I2 (de)
PT (3) PT670896E (de)
SE (1) SE2210947T5 (de)
WO (1) WO1994012628A1 (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040064855A1 (en) * 1988-02-26 2004-04-01 Large Scale Biology Corporation Production of lysosomal enzymes in plants by transient expression
US6846968B1 (en) * 1988-02-26 2005-01-25 Large Scale Biology Corporation Production of lysosomal enzymes in plants by transient expression
US5179023A (en) * 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
WO1994023070A1 (en) * 1993-03-26 1994-10-13 New York Blood Center, Inc. RECOMBINANT α-N-ACETYLGALACTOSAMINIDASE ENZYME AND cDNA ENCODING SAID ENZYME
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
MX340738B (es) * 1996-09-13 2016-07-22 Shire Human Genetic Therapies Terapia para deficiencia de a-galactosidasa a.
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
AU2012227349B2 (en) * 1996-09-13 2015-12-24 Shire Human Genetic Therapies, Inc. Therapy for alpha-galactosidase A deficiency
IL155588A0 (en) * 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US6455037B1 (en) * 1996-11-01 2002-09-24 Mount Sinai School Of Medicine Of The City University Of New York Cells expressing an αgala nucleic acid and methods of xenotransplantation
US6210666B1 (en) 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
EP1658857A1 (de) * 1997-10-29 2006-05-24 Genzyme Corporation Zusammensetzungen und Methoden zum Behandlung von lysosomalen Lagerungskrankheit
IL135578A0 (en) * 1997-10-29 2001-05-20 Genzyme Corp Compositions and methods for treating lysosomal storage disease
IL143558A0 (en) * 1998-12-23 2002-04-21 Regeneron Pharma Method of enhancing the biological activity of ligands
AU2012241170B2 (en) * 1999-03-11 2016-07-28 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
AU2016250357B2 (en) * 1999-03-11 2018-11-01 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
CN1312383A (zh) * 2000-03-07 2001-09-12 上海博德基因开发有限公司 一种新的多肽——人alpha－半乳糖苷酶A－11和编码这种多肽的多核苷酸
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
WO2002087510A2 (en) * 2001-04-30 2002-11-07 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
JP4742191B2 (ja) * 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
US7767415B2 (en) 2001-09-25 2010-08-03 Velico Medical, Inc. Compositions and methods for modifying blood cell carbohydrates
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US6905856B2 (en) * 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US20030124652A1 (en) * 2001-12-21 2003-07-03 Novazyme Pharmaceuticals, Inc. Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
US6800472B2 (en) * 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
WO2003086452A2 (en) * 2002-04-05 2003-10-23 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy
DK1503788T3 (da) * 2002-04-25 2011-10-17 Shire Human Genetic Therapies Behandling af alpha-galactosidase A-deficiens
EP2857036B1 (de) 2003-01-31 2016-12-21 Mount Sinai School of Medicine of New York University Kombinationstherapie zur behandlung von proteinmangelstörungen
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
CA2545433A1 (en) * 2003-11-12 2005-05-26 Amicus Therapeutics Inc. Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
CA2553955C (en) * 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US8889127B2 (en) * 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
CN101389273B (zh) * 2004-08-05 2012-09-05 贝勒研究院 基因或药物递送系统
EP3782655A1 (de) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. Verfahren zur behandlung der pompe-krankheit unter verwendung von 1-deoxynojirimycin und derivaten
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
BRPI0618583A2 (pt) * 2005-11-18 2011-09-06 Tokyo Metropolitan Org Med Res enzima altamente funcional tendo especifidade ao substrato modificada
HRP20120994T1 (hr) 2006-02-07 2012-12-31 Shire Human Genetic Therapies, Inc. Stabilizirana smjesa glukocerebrozidaze
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
CA2647524C (en) * 2006-04-05 2019-11-26 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2099523A2 (de) * 2006-11-13 2009-09-16 ZyStor Therapeutics , Inc. Verfahren zur behandlung von pompe-krankheit
AU2008246928B2 (en) 2007-05-07 2014-04-17 Protalix Ltd. Large scale disposable bioreactor
CA2696699A1 (en) * 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
EP2946785B1 (de) * 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Verfahren zur vorhersage der reaktion auf die behandlung von krankheiten mit pharmakologischen chaperonen
WO2009132130A2 (en) 2008-04-22 2009-10-29 The Rockefeller University Methods of identifying anti-inflammatory compounds
JP5627571B2 (ja) 2008-05-07 2014-11-19 バイオマリン ファーマシューティカル インコーポレイテッド リソソーム標的化ペプチドおよびその使用
US8592555B2 (en) * 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
KR20110076906A (ko) * 2008-09-30 2011-07-06 아보트 러보러터리즈 개선된 ｒｎａ 디스플레이 방법
SG195555A1 (en) 2008-12-24 2013-12-30 Emd Millipore Corp Caustic stable chromatography ligands
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
EP3679942A1 (de) 2009-06-17 2020-07-15 BioMarin Pharmaceutical Inc. Formulierungen für lysosomale enzyme
NZ713967A (en) 2009-07-28 2017-01-27 Shire Human Genetic Therapies Compositions and methods for treating gaucher disease
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
WO2011108451A1 (ja) * 2010-03-01 2011-09-09 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
US20130017169A1 (en) 2010-03-02 2013-01-17 Protalix Ltd. Multimeric forms of therapeutic proteins and uses thereof
SI2865751T1 (sl) 2010-03-02 2017-01-31 Protalix Ltd. Stabilizirana alfa-galaktozidaza in njene uporabe
EP2595651B1 (de) 2010-07-19 2017-03-29 Shire Human Genetic Therapies, Inc. Kodonoptimierte zelllinie für den mannoserezeptor-c vom typ 1 (mrc1) und anwendungen davon
US8679478B2 (en) 2010-10-04 2014-03-25 Duke University Methods of lysosomal storage disease therapy
WO2012051567A2 (en) 2010-10-15 2012-04-19 The Trustees Of Columbia University In The City Of New York Obesity-related genes and their proteins and uses thereof
WO2012061537A2 (en) 2010-11-02 2012-05-10 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
KR101883803B1 (ko) 2011-01-20 2018-07-31 프로탈릭스 리미티드 식물 및 식물 세포에서 알파-갈락토시다제의 발현용 핵산 작제물
SG186552A1 (en) 2011-06-08 2013-01-30 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
LT2753346T (lt) 2011-09-07 2020-08-10 Mount Sinai School Of Medicine Ceramidazė ir ląstelių diferenciacija
CN104519905A (zh) 2012-03-02 2015-04-15 夏尔人类遗传性治疗公司 用于治疗iii型戈谢病的组合物和方法
KR20230066482A (ko) 2012-03-07 2023-05-15 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
ES2897825T3 (es) 2012-06-01 2022-03-02 Icahn School Med Mount Sinai Niveles de ceramida en el tratamiento y prevención de infecciones
WO2014016873A1 (en) * 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Method for production of recombinant human alpha-galactosidase a
JP6226435B2 (ja) * 2012-07-26 2017-11-08 Ｊｃｒファーマ株式会社 組換えヒトα−ガラクトシダーゼＡの製造方法
PT2968479T (pt) 2013-03-14 2019-08-07 Icahn School Med Mount Sinai Composições terapêuticas de ceramidase ácida e métodos de fabrico e utilização
AU2014228231B2 (en) * 2013-03-15 2019-02-21 Amicus Therapeutics, Inc. Chemical crosslinkers
BR112016005545B1 (pt) * 2013-09-16 2021-06-01 Genzyme Corporation Método de processamento de uma cultura de células de mamífero
TWI793159B (zh) 2013-10-23 2023-02-21 美商健臻公司 重組醣蛋白及其用途
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
CN114540327B (zh) 2014-09-30 2026-03-24 阿米库斯治疗学公司 具有增强的碳水化合物的高强度酸性α-葡糖苷酶
WO2016116966A1 (en) 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
US9981021B1 (en) 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
AU2016321298A1 (en) 2015-09-09 2018-03-29 The Trustees Of Columbia University In The City Of New York Reduction of ER-MAM localized APP-C99 and methods of treating Alzheimer's Disease
WO2017049157A1 (en) 2015-09-18 2017-03-23 Duke University Methods and compositions for the treatment of steatosis-associated disorders
KR20250007693A (ko) 2015-12-30 2025-01-14 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
AU2017239641A1 (en) 2016-03-30 2018-10-18 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
CA3019354A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
WO2018071814A1 (en) 2016-10-14 2018-04-19 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
SMT202300187T1 (it) 2017-05-15 2023-07-20 Amicus Therapeutics Inc Alfa-glucosidasi acida umana ricombinante
RU2698460C1 (ru) * 2019-03-28 2019-08-27 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Способ получения рекомбинантной в-1,4-галактозидазы bgaa из streptococcus pneumoniae
EP3996696A1 (de) 2019-07-09 2022-05-18 Genethon Behandlung von glykogenspeichererkrankung (gsd)
CN112795583A (zh) * 2020-11-16 2021-05-14 上海大学 重组唾液酸外切酶的制备方法、表达基因、重组表达载体及构建方法
EP4244360A4 (de) * 2020-11-16 2025-05-07 Beijing SoloBio Genetechnology Company Ltd. Rekombinante adeno-assoziierte viren mit erhöhtem lebertropismus und verwendungen davon
AU2022261885A1 (en) * 2021-04-20 2023-11-09 Walking Fish Therapeutics, Inc. Engineering b cell-based protein factories to treat serious diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH585793A5 (de) * 1974-02-01 1977-03-15 Nestle Sa
JPS5322158B2 (de) * 1974-05-02 1978-07-06
IT1130242B (it) * 1980-02-01 1986-06-11 Anic Spa Procedimento per la produzione dell'enzima alfa-galattosidasi e per l'idrolisi del raffinosio mediante l'impiego dell'enzima stesso
US4925796A (en) * 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
EP0463109A4 (en) * 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
US5032519A (en) * 1989-10-24 1991-07-16 The Regents Of The Univ. Of California Method for producing secretable glycosyltransferases and other Golgi processing enzymes
DE4028800A1 (de) * 1990-09-11 1992-03-12 Behringwerke Ag Gentechnische sialylierung von glykoproteinen
US5382524A (en) * 1990-10-24 1995-01-17 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-n-acetylgalactosaminidase

Also Published As

Publication number Publication date
EP1942189A2 (de) 2008-07-09
AU5681794A (en) 1994-06-22
IL107814A (en) 2012-12-31
US5401650A (en) 1995-03-28
ES2168101T3 (es) 2002-06-01
ATE464386T1 (de) 2010-04-15
JP2004121260A (ja) 2004-04-22
JP3598302B2 (ja) 2004-12-08
AU691795B2 (en) 1998-05-28
PT1942189E (pt) 2010-05-28
IL107814A0 (en) 1994-02-27
DE69334327D1 (de) 2010-05-27
CA2150555A1 (en) 1994-06-09
DE69331550T3 (de) 2006-06-29
LU91703I2 (fr) 2010-08-24
ES2431293T3 (es) 2013-11-25
US5580757A (en) 1996-12-03
DE69331550D1 (de) 2002-03-21
DK1942189T3 (da) 2010-06-07
EP0670896B2 (de) 2005-04-27
WO1994012628A1 (en) 1994-06-09
EP1942189A3 (de) 2008-09-10
DE69331550T2 (de) 2002-09-26
EP2210947A3 (de) 2010-10-06
ATE213020T1 (de) 2002-02-15
IL220131A0 (en) 2012-07-31
PT2210947E (pt) 2013-10-23
DE122010000028I1 (de) 2010-08-12
PT670896E (pt) 2002-07-31
DK0670896T3 (da) 2002-05-27
EP1020528A3 (de) 2000-10-04
EP1942189B1 (de) 2010-04-14
JPH08503615A (ja) 1996-04-23
EP0670896A1 (de) 1995-09-13
EP0670896A4 (de) 1997-08-20
CA2150555C (en) 2010-11-02
EP0670896B1 (de) 2002-02-06
DK2210947T3 (da) 2013-10-07
ES2344431T3 (es) 2010-08-26
JP4005629B2 (ja) 2007-11-07
IL200005A (en) 2013-09-30
EP2210947B1 (de) 2013-07-17
LU91704I2 (fr) 2010-08-24
EP2210947A2 (de) 2010-07-28
EP1020528A2 (de) 2000-07-19
IL220132A0 (en) 2012-07-31
ES2168101T5 (es) 2005-10-16

Similar Documents

Publication Publication Date Title
SE2210947T5 (de)
AU2443488A (en) Dna-molecules coding for fmdh control regions and structured gene for a protein having fmdh-activity and their uses
DE60029091D1 (de) Verfahren zur herstellung von diphtheria toxin
ES8606489A1 (es) Un metodo de producir una proteina de interleuquina-2-humana no glicosilada sustancialmente pura
EP0390819A4 (en) Mass production in liquid culture of insect-killing nematodes
HU9801420D0 (en) Process for producing l-amino acids by fermentition
EP0111389A3 (de) Wesentlich sauberes Schweinewachstumshormon, DNS-Sequenzen dafür und Expressionsvektoren und transfektierte Mikroorganismen zur Herstellung von Schweinewachstumshormon
DE68915692D1 (de) Fermentationsverfahren zur Herstellung von 2-Keto-L-Gulonsäure.
KR910006483A (ko) 재조합 아프로티닌 변이체, 균질하게 프로세싱된 아프로티닌 변이체의 미생물을 이용한 유전공학적 제조 방법 및 그의 치료 용도
ATE30246T1 (de) Verfahren zur herstellung reifer proteine aus schmelzproteinen hergestellt in pro- oder eukaryotischen zellen.
ES2088911T3 (es) Gen de la proteasa i de achromobacter y el producto de este gen.
AU1090688A (en) Synthetic porcine growth hormone
JPS5774093A (en) Method of increasing interferon production
ES8702487A1 (es) Procedimiento para cultivar microorganismos en aerobiosis enun medio nutritivo liquido sometido a una oxigenacion
ATE145670T1 (de) Verfahren zur fermentativen herstellung von 2- hydroxyphenylessigsäure
CA2133345A1 (en) A Method of Limiting the Survival of Genetically Engineered Microorganisms in Their Environment
DE3868712D1 (de) Ein neues antibiotikum, fumifungin, ein mikrobielles verfahren zu seiner herstellung und seine verwendung als arzneimittel.
DE69429757D1 (de) Verfahren zur Herstellung einer Substanz
JPS5668394A (en) Production of d(-)-beta-hydroxyisobutyric acid
KR950018453A (ko) 콜라게네이즈 인지부위를 가진 재조합 인간 성장 호르몬
KR940021729A (ko) 효모로부터 재조합 히루딘을 생산하는 방법
EP0169907A4 (de) Herstellungsverfahren von polypeptiden mit zutat von zucker.